Patents by Inventor Vishva M. Dixit
Vishva M. Dixit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6713061Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.Type: GrantFiled: April 21, 2000Date of Patent: March 30, 2004Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Vishva M. Dixit, Reiner L. Gentz, Patrick J. Dillon
-
Patent number: 6680171Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of INFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.Type: GrantFiled: January 21, 2000Date of Patent: January 20, 2004Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Jian Ni, Craig A. Rosen, Vishva M. Dixit, Reiner L. Gentz, Joseph J. Kenny
-
Patent number: 6653452Abstract: The present invention relates to a novel IRAK-2 protein which is a member of the IL-1 signaling pathway. In particular, isolated nucleic acid molecules are provided encoding the human IRAK-2 protein. IRAK-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting IRAK-2 related disorders and therapeutic methods for treating IRAK-2 related disorders.Type: GrantFiled: February 2, 2001Date of Patent: November 25, 2003Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Jian Ni, Ping Feng, Marta Muzio, Vishva M. Dixit
-
Patent number: 6623938Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.Type: GrantFiled: January 21, 1998Date of Patent: September 23, 2003Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Jian Ni, Craig A. Rosen, Vishva M. Dixit, Reiner L. Gentz, Joseph J. Kenny
-
Publication number: 20030108516Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.Type: ApplicationFiled: June 21, 2002Publication date: June 12, 2003Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Publication number: 20030096288Abstract: The present invention relates to a novel molecule involved in the process of apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human RAIDD protein and splice variants thereof—referred to as RAIDD-SV1 and RAIDD-SV2. RAIDD polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of RAIDD activity.Type: ApplicationFiled: November 5, 2002Publication date: May 22, 2003Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Vishva M. Dixit
-
Patent number: 6562797Abstract: This invention provides a novel purified mammalian protein designated FADD having the ability to bind the cytoplasmic region or domain of the Fas receptor. Also provided are nucleic acid molecules that encode the mammalian protein which binds the intracellular domain of Fas as well as methods for using the proteins and nucleic acid molecules.Type: GrantFiled: September 22, 1998Date of Patent: May 13, 2003Assignee: The Regents of the University of MichiganInventors: Vishva M. Dixit, Karen O'Rourke
-
Publication number: 20030087339Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.Type: ApplicationFiled: January 21, 1998Publication date: May 8, 2003Inventors: JIAN NI, CRAIG A. ROSEN, VISHVA M. DIXIT, REINER L. GENTZ, JOSEPH J. KENNY
-
Publication number: 20030073187Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.Type: ApplicationFiled: August 23, 2002Publication date: April 17, 2003Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Publication number: 20030036168Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.Type: ApplicationFiled: August 23, 2002Publication date: February 20, 2003Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Patent number: 6495322Abstract: The present invention relates to a novel molecule involved in the process of apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human RAIDD protein and splice variants thereof—referred to as RAIDD-SV1 and RAIDD-SV2. RAIDD polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of RAIDD activity.Type: GrantFiled: April 7, 2000Date of Patent: December 17, 2002Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Jian Ni, Vishva M. Dixit
-
Patent number: 6461823Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.Type: GrantFiled: November 24, 1999Date of Patent: October 8, 2002Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Patent number: 6433147Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.Type: GrantFiled: May 5, 2000Date of Patent: August 13, 2002Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Publication number: 20020099177Abstract: The present invention relates to a novel IRAK-2 protein which is a member of the IL-1 signaling pathway. In particular, isolated nucleic acid molecules are provided encoding the human IRAK-2 protein. IRAK-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting IRAK-2 related disorders and therapeutic methods for treating IRAK-2 related disorders.Type: ApplicationFiled: February 2, 2001Publication date: July 25, 2002Inventors: Jian Ni, Ping Feng, Marta Muzio, Vishva M. Dixit
-
Patent number: 6342363Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.Type: GrantFiled: January 27, 1998Date of Patent: January 29, 2002Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Patent number: 6294169Abstract: Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such ICE LAP-6 for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.Type: GrantFiled: April 27, 1999Date of Patent: September 25, 2001Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation, University of MichiganInventors: Vishva M. Dixit, Wei-Wu He, Kristine K. Kikly, Steven M. Ruben
-
Patent number: 6222019Abstract: The present invention relates to a novel IRAK-2 protein which is a member of the IL-1 signaling pathway. In particular, isolated nucleic acid molecules are provided encoding the human IRAK-2 protein. IRAK-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting IRAK-2 related disorders and therapeutic methods for treating IRAK-2 related disorders.Type: GrantFiled: May 7, 1999Date of Patent: April 24, 2001Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Ping Feng, Marta Muzio, Vishva M. Dixit
-
Patent number: 6130079Abstract: The present invention relates to a novel molecule involved in the process of apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human RAIDD protein and splice variants thereof--referred to as RAIDD-SV1 and RAIDD-SV2. RAIDD polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of RAIDD activity.Type: GrantFiled: December 19, 1997Date of Patent: October 10, 2000Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Vishva M. Dixit
-
Patent number: 6060238Abstract: This invention provides non-naturally occurring and isolated naturally occurring nucleic acid molecules which encode proteins designated Yama. This invention also provides the polypeptides and proteins encoded by these nucleic acids as well as the purified native polypeptides or proteins. Also provided by this invention is a non-naturally occurring nucleic acid molecule encoding mutant CrmA protein and a dominant inhibitory Yama. Vectors and host cells containing these nucleic acid molecules are further provided. Methods of modulating a cellular function regulated by the Fas receptor pathway in a cell is provided herein. In one aspect, this method comprises introducing into the cell a nucleic acid molecule coding for a gene product having CrmA biological activity such as dominant inhibitory Yama or alternatively, the CrmA gene product. Yama nucleic acid molecules and proteins also can be introduced into the cell to modulate the cellular function regulated by the Fas receptor.Type: GrantFiled: February 9, 1996Date of Patent: May 9, 2000Assignee: The Regents of the University of MichiganInventor: Vishva M. Dixit
-
Patent number: 6046007Abstract: Methods and compositions for preventing or inhibiting apoptosis are provided by this invention. The methods require introducing into a cell which may undergo apoptosis a nucleic acid molecule coding for a gene product having crmA biological activity or a crmA polypeptide. This invention also provides compositions and methods for maintaining T cell viability in a subject infected with the human immunodeficiency virus (HIV), by administering to the subject an effective amount of a nucleic acid molecule coding for a gene product having crmA biological activity or the gene product itself.Type: GrantFiled: March 17, 1999Date of Patent: April 4, 2000Assignee: The Regents of the University of MichiganInventor: Vishva M. Dixit